Physician profile
Pami Jo Taylor
NPI 1477592632
$10,288.99
in general payments reported to CMS, 2019-2025
40 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,327 · 2020: $1,060 · 2021: $1,627 · 2022: $1,617 · 2023: $1,511 · 2024: $1,648 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,658.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,158.46 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,091.99 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,024.55 | 2019-2025 | |
| Abbvie INC. | $1,016.26 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Amgen INC. | $851.90 | 2019-2025 | Evenity, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $668.95 | 2019-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $565.77 | 2019-2025 | Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $523.09 | 2019-2024 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $389.89 | 2019-2025 | Arexvy, Shingrix, Boostrix |
| Astellas Pharma US INC | $283.38 | 2019-2021 | |
| Novo Nordisk INC | $257.77 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $232.29 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $209.93 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $208.06 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $186.71 | 2023-2025 | Rexulti |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $180.28 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $169.37 | 2019-2022 | |
| Amarin Pharma, INC. | $154.20 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $130.85 | 2019-2023 | Camzyos |
| Abbott Laboratories | $113.94 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Eterna |
| Esperion Therapeutics, INC. | $105.52 | 2020-2024 | Nexletol |
| Exact Sciences Corporation | $102.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $89.34 | 2019-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $85.39 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.45 | 2019-2025 | Trintellix |
| Boston Scientific Corporation | $73.20 | 2022-2025 | Watchman Flx |
| Mylan Specialty L.P. | $72.94 | 2023 | Yupelri |
| Sumitomo Pharma America, INC. | $41.74 | 2024 | Gemtesa |
| Allergan, INC. | $25.98 | 2020 | |
| Shire North American Group INC | $25.35 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $23.94 | 2019-2020 | |
| Biogen, INC. | $19.55 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $18.31 | 2019 | |
| Radius Health, INC. | $16.61 | 2019 | |
| Seqirus USA INC | $15.98 | 2025 | Fluad, Flucelvax |
| Biohaven Pharmaceuticals, INC. | $14.81 | 2021 | |
| Shield Therapeutics INC | $14.50 | 2024 | |
| Paratek Pharmaceuticals, INC. | $13.85 | 2021 | |
| Bausch Health US, LLC | $13.64 | 2021 | |
| Dexcom, INC. | $13.56 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pami Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.